Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer
Autore:
Marana, HRC; da Silva, JS; de Andrade, JM;
Indirizzi:
Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Obstet & Gynecol, BR-14049900Ribeirao Preto, SP, Brazil Univ Sao Paulo Ribeirao Preto SP Brazil BR-14049900 BCo Preto, SP, Brazil Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Microbiol Immunol & Parasitol, BR-14049900 Ribeirao Preto, SP, Brazil Univ Sao Paulo Ribeirao Preto SP Brazil BR-14049900 BCo Preto, SP, Brazil
Titolo Testata:
GYNECOLOGIC ONCOLOGY
fascicolo: 3, volume: 78, anno: 2000,
parte:, 1
pagine: 318 - 323
SICI:
0090-8258(200009)78:3<318:NCAITP>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
NATURAL-KILLER-CELL; STIMULATORY FACTOR NKSF; INTERLEUKIN-12; DISEASE; LYMPHOCYTES; ANTITUMOR; CYTOKINE; SURVIVAL; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Marana, HRC Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Obstet & Gynecol,BR-14049900Ribeirao Preto, SP, Brazil Univ Sao Paulo Ribeirao Preto SP Brazil BR-14049900 BC Brazil
Citazione:
H.R.C. Marana et al., "NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer", GYNECOL ONC, 78(3), 2000, pp. 318-323

Abstract

Objective. Little is known about the impact of neoadjuvant chemotherapy oncell-mediated immunity in patients with advanced cervical cancers. Patients and methods. We have studied 24 patients with advanced cervical cancer submitted to neoadjuvant chemotherapy (CT) using cia-platinum (100 mg/m(2)/cycle) and bleomycin (30 mg/cycle). The cell-mediated immunity parameters available before and after CT were NK cells, CD4(+)/CD28 and CD8(+)/CD28 T-lymphocyte numbers, PBMC cytotoxicity, and modification of this parameter with "in vitro" addition of IL-12,Results. The number of NK cells was higher before CT (P < 0.008) in 13 patients who presented a good clinical response to treatment, compared to 11 patients with a poor clinical response. In addition, PBMC cytotoxicity (P < 0.001), CD4(+) and CD8(+) T-lymphocyte values (P < 0.0047), and CD8(+)/CD28(+) cells were also higher in the group with a good response compared with the group with a poor response. Addition of IL-12 to the medium increased the lytic capacity of PBMC after CT only in the group with a good clinical response (P < 0.05). Conclusions. NK cell numbers, CD8(+) T-cell levels, and CD8(+)/ CD28(+) cell levels can be used as prognostic factors before CT. Our results suggest that patients with a poor response have lower lytic activity per NK cell and are refractory to IL-12 stimulation, probably as a result of the reduced expression of IL-12 receptors or of an intracellular defect in the mechanism of transduction. These observations also provide support for human clinical trials of IL-12 and neoadjuvant CT in patients with cervical cancer. (C)2000 Academic Press.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 11:09:49